Unresectable Hepatic Metastasis of Uveal Melanoma: Hepatic Chemosaturation with High-Dose Melphalan—Long-Term Overall Survival Negatively Correlates with Tumor Burden

Introduction. Percutaneous hepatic perfusion with melphalan (PHP-M) for hepatic metastasis of uveal melanoma (LMUM) achieves high local response rates, but the individual clinical benefit is poorly defined. We aimed to determine cofactors of response and clinical outcomes including the probability o...

Full description

Saved in:
Bibliographic Details
Main Authors: R. Brüning, M. Tiede, M. Schneider, P. Wohlmuth, H. Weilert, K. Oldhafer, A. Stang
Format: Article
Language:English
Published: Wiley 2020-01-01
Series:Radiology Research and Practice
Online Access:http://dx.doi.org/10.1155/2020/5672048
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832566485645524992
author R. Brüning
M. Tiede
M. Schneider
P. Wohlmuth
H. Weilert
K. Oldhafer
A. Stang
author_facet R. Brüning
M. Tiede
M. Schneider
P. Wohlmuth
H. Weilert
K. Oldhafer
A. Stang
author_sort R. Brüning
collection DOAJ
description Introduction. Percutaneous hepatic perfusion with melphalan (PHP-M) for hepatic metastasis of uveal melanoma (LMUM) achieves high local response rates, but the individual clinical benefit is poorly defined. We aimed to determine cofactors of response and clinical outcomes including the probability of long-term (5-years) overall survival (OS) in PHP-M-treated patients with LMUM. Patients and Methods. We retrospectively reviewed clinicopathological, radiological, and outcome data of 19 patients with unresectable LMUM treated with 43 PHP-M (median 2 PHP-M) between 2014 and 2019. Tumor response and adverse events were evaluated using RECIST 1.1 and the Clavien–Dindo classification. Kaplan–Meier methods and Cox regression hazard proportional models were used. Results. Of 19 patients, 10 (53%) achieved a partial response (PR) and 9 (47%) had stable disease (SD). There was no progressive disease (PD) and no adverse events exceeding Clavien–Dindo grade IV. Median OS was 16.7 months after the first PHP-M treatment and 26.4 months after initial diagnosis. Low hepatic tumor volume (median of 10 mL vs. 150 mL) was an independent predictor of favorable OS (hazard ratio (95% confidence interval): 0.190 (0.041, 0.893); p<0.05), and female patients were at a lower risk compared with males (0.146 (0.017, 1.240)). Estimates of the overall survival were 0.213 (0.0449, 1) from first imaging (95% confidence interval) to 5 years and 0.793 (0.609, 1) and 0.604 (0.380, 0.960) for 1 and 2 years after chemosaturation, respectively. Discussion. PHP-M for nonresectable LMUV provides a safe and locally efficient liver-directed procedure that offers patients a chance for long-term OS, especially for patients with a low hepatic tumor burden.
format Article
id doaj-art-756ce7eec1b844f898ba516063565920
institution Kabale University
issn 2090-1941
2090-195X
language English
publishDate 2020-01-01
publisher Wiley
record_format Article
series Radiology Research and Practice
spelling doaj-art-756ce7eec1b844f898ba5160635659202025-02-03T01:04:00ZengWileyRadiology Research and Practice2090-19412090-195X2020-01-01202010.1155/2020/56720485672048Unresectable Hepatic Metastasis of Uveal Melanoma: Hepatic Chemosaturation with High-Dose Melphalan—Long-Term Overall Survival Negatively Correlates with Tumor BurdenR. Brüning0M. Tiede1M. Schneider2P. Wohlmuth3H. Weilert4K. Oldhafer5A. Stang6Radiology and Neuroradiology, Asklepios Hospital Barmbek, Ruebenkamp 220, 22307 Hamburg, GermanyRadiology and Neuroradiology, Asklepios Hospital Barmbek, Ruebenkamp 220, 22307 Hamburg, GermanyRadiology and Neuroradiology, Asklepios Hospital Barmbek, Ruebenkamp 220, 22307 Hamburg, GermanyBiostatistics, ProResearch, Asklepios Hospital St. Georg, Lohmuehlenstrasse 5, 20099 Hamburg, GermanyOncology, Asklepios Hospital Barmbek, Ruebenkamp 220, 22307 Hamburg, GermanyBiostatistics, ProResearch, Asklepios Hospital St. Georg, Lohmuehlenstrasse 5, 20099 Hamburg, GermanyOncology, Asklepios Hospital Barmbek, Ruebenkamp 220, 22307 Hamburg, GermanyIntroduction. Percutaneous hepatic perfusion with melphalan (PHP-M) for hepatic metastasis of uveal melanoma (LMUM) achieves high local response rates, but the individual clinical benefit is poorly defined. We aimed to determine cofactors of response and clinical outcomes including the probability of long-term (5-years) overall survival (OS) in PHP-M-treated patients with LMUM. Patients and Methods. We retrospectively reviewed clinicopathological, radiological, and outcome data of 19 patients with unresectable LMUM treated with 43 PHP-M (median 2 PHP-M) between 2014 and 2019. Tumor response and adverse events were evaluated using RECIST 1.1 and the Clavien–Dindo classification. Kaplan–Meier methods and Cox regression hazard proportional models were used. Results. Of 19 patients, 10 (53%) achieved a partial response (PR) and 9 (47%) had stable disease (SD). There was no progressive disease (PD) and no adverse events exceeding Clavien–Dindo grade IV. Median OS was 16.7 months after the first PHP-M treatment and 26.4 months after initial diagnosis. Low hepatic tumor volume (median of 10 mL vs. 150 mL) was an independent predictor of favorable OS (hazard ratio (95% confidence interval): 0.190 (0.041, 0.893); p<0.05), and female patients were at a lower risk compared with males (0.146 (0.017, 1.240)). Estimates of the overall survival were 0.213 (0.0449, 1) from first imaging (95% confidence interval) to 5 years and 0.793 (0.609, 1) and 0.604 (0.380, 0.960) for 1 and 2 years after chemosaturation, respectively. Discussion. PHP-M for nonresectable LMUV provides a safe and locally efficient liver-directed procedure that offers patients a chance for long-term OS, especially for patients with a low hepatic tumor burden.http://dx.doi.org/10.1155/2020/5672048
spellingShingle R. Brüning
M. Tiede
M. Schneider
P. Wohlmuth
H. Weilert
K. Oldhafer
A. Stang
Unresectable Hepatic Metastasis of Uveal Melanoma: Hepatic Chemosaturation with High-Dose Melphalan—Long-Term Overall Survival Negatively Correlates with Tumor Burden
Radiology Research and Practice
title Unresectable Hepatic Metastasis of Uveal Melanoma: Hepatic Chemosaturation with High-Dose Melphalan—Long-Term Overall Survival Negatively Correlates with Tumor Burden
title_full Unresectable Hepatic Metastasis of Uveal Melanoma: Hepatic Chemosaturation with High-Dose Melphalan—Long-Term Overall Survival Negatively Correlates with Tumor Burden
title_fullStr Unresectable Hepatic Metastasis of Uveal Melanoma: Hepatic Chemosaturation with High-Dose Melphalan—Long-Term Overall Survival Negatively Correlates with Tumor Burden
title_full_unstemmed Unresectable Hepatic Metastasis of Uveal Melanoma: Hepatic Chemosaturation with High-Dose Melphalan—Long-Term Overall Survival Negatively Correlates with Tumor Burden
title_short Unresectable Hepatic Metastasis of Uveal Melanoma: Hepatic Chemosaturation with High-Dose Melphalan—Long-Term Overall Survival Negatively Correlates with Tumor Burden
title_sort unresectable hepatic metastasis of uveal melanoma hepatic chemosaturation with high dose melphalan long term overall survival negatively correlates with tumor burden
url http://dx.doi.org/10.1155/2020/5672048
work_keys_str_mv AT rbruning unresectablehepaticmetastasisofuvealmelanomahepaticchemosaturationwithhighdosemelphalanlongtermoverallsurvivalnegativelycorrelateswithtumorburden
AT mtiede unresectablehepaticmetastasisofuvealmelanomahepaticchemosaturationwithhighdosemelphalanlongtermoverallsurvivalnegativelycorrelateswithtumorburden
AT mschneider unresectablehepaticmetastasisofuvealmelanomahepaticchemosaturationwithhighdosemelphalanlongtermoverallsurvivalnegativelycorrelateswithtumorburden
AT pwohlmuth unresectablehepaticmetastasisofuvealmelanomahepaticchemosaturationwithhighdosemelphalanlongtermoverallsurvivalnegativelycorrelateswithtumorburden
AT hweilert unresectablehepaticmetastasisofuvealmelanomahepaticchemosaturationwithhighdosemelphalanlongtermoverallsurvivalnegativelycorrelateswithtumorburden
AT koldhafer unresectablehepaticmetastasisofuvealmelanomahepaticchemosaturationwithhighdosemelphalanlongtermoverallsurvivalnegativelycorrelateswithtumorburden
AT astang unresectablehepaticmetastasisofuvealmelanomahepaticchemosaturationwithhighdosemelphalanlongtermoverallsurvivalnegativelycorrelateswithtumorburden